A panel of plasma microRNAs improves the assessment of surrogate markers of cardiovascular disease in rheumatoid arthritis patients
Authors' conclusion
Plasmatic expression of microRNA-24, 96, 103, 125a, 132, 146, 191, 223 and Let7a were associated with surrogate markers of CV disease and could be predictors of CV risk in patients with RA.
Study context
- Population
- Patients with RA; association of a 10-microRNA plasma panel with surrogate markers of subclinical arteriosclerosis (carotid intima-media thickness (cIMT), carotid plaque presence (cPP), pulse wave velocity (PWV), distensibility)
- Participants
- 199 patients
- Outcome
- Association of plasma microRNAs with surrogate markers of subclinical arteriosclerosis (cIMT, cPP, PWV and distensibility)
Methodological detailsmultivariate models, partial least square discriminant analysis
- Multivariate models
- Partial least square discriminant analysis
Main finding
As reported in the abstract
- microRNA-24 with cIMT globally, β
- 15.48
- microRNA-125a with cIMT globally, β
- 9.93
- microRNA-132 with cIMT globally, β
- 11.52
- microRNA-146 with cIMT globally, β
- 15.12
- microRNA-191 with cIMT globally, β
- 13.25
- microRNA-223 with cIMT globally, β
- 13.30
- microRNA-24 with cPP in men, OR
- 0.41
- microRNA-146 with cPP in men, OR
- 0.36
- Let7a with cPP in men, OR
- 0.23
- microRNA-96 with PWV in male patients, β
- −0.28
Observational data: associations, not effects.
Further findings
Subgroups: high DAS28 and earlier tertiles of disease duration
- Several miRNAs also associated with cIMT, cPP and arterial stiffness in the high DAS28 group and in the earlier tertile groups of disease duration
Original publication
A panel of plasma microRNAs improves the assessment of surrogate markers of cardiovascular disease in rheumatoid arthritis patients. Rheumatology (Oxford). Published 1 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →